24
Feb
2025
Defend Young Scientists
Biotech thrives on the creative dynamism of young scientists. Always has. Young scientists are under pressure. NIH grants are on hold. If the NIH budget is gutted, and a generation is forced to find other ways to earn a living, then the biotech industry will lose. It might not be clear for the next couple of quarters or next couple... Read More
18
Feb
2025
Defend the FDA
We need a competent, well-supported, tough and independent food and drug regulator in this country. We need that independent cop on the beat so we can have confidence that the medicines, vaccines, diagnostics and devices at the core of modern healthcare have passed the scrutiny of an uncorrupted, scientifically grounded and ethical group of people working in the public interest.... Read More
13
Feb
2025
RFK Jr. in Power, NIH and FDA on the Chopping Block, & Interest Rates Loom Large
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2025
Defend the NIH
Too many people don’t believe anymore in the American Dream. But if you can’t dream big, you can’t accomplish big things. Today, the National Institutes of Health — biomedical science itself — is under attack. It needs us to stand up in its defense. The NIH is an engine of the American Dream. The NIH, with a $47.7 billion a... Read More
11
Feb
2025
Building a Fully Integrated Biopharma For the Muscle: Robert Blum on The Long Run
Robert Blum is today’s guest on The Long Run. Robert is the CEO of South San Francisco-based Cytokinetics. He joined the company back in the beginning in 1998 and became CEO in 2007. This company, and Robert’s career, are emblematic of what this show is about — The Long Run that it takes to develop new medicines. The company has... Read More
6
Feb
2025
Billion Cells Project, Alumis Merges, BMS Cuts Deeper
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2025
Timmerman Report Turns 10
Timmerman Report is 10 years old today. On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual — and fiercely independent — biotech journalism. The past 10 years of biotech have been remarkable. I’ve had a front-row seat. It’s... Read More
30
Jan
2025
Akero Nails MASH Trial, Cargo Crashes, & Maze, Metsera IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2025
Looking at Live Cells and How They Interact at Scale: Mostafa Ronaghi on The Long Run
Mostafa Ronaghi is today’s guest on The Long Run. He is the co-founder and an executive board member at Foster City, Calif.-based Cellanome. Mostafa is a molecular biologist and technology developer. He is an inventor of pyrosequencing methods for DNA sequencing, and is best known for his work as chief technology officer at Illumina during its glory days from 2008-2021.... Read More
22
Jan
2025
Party Like It’s 2015: Celebrate the 10th Anniversary of Timmerman Report
The Timmerman Report is gearing up for the 10th Anniversary. Time to Party! Join a stellar cast of biotech leaders at the TR10 East Coast Party. This free and fun event will celebrate the 10th anniversary of Timmerman Report. Don’t miss the toasts and roasts of TR Founder Luke Timmerman. Listen for a few predictions about the next 10 years of... Read More
16
Jan
2025
J&J Doubles Down on Neuro, Lilly Acquires Scorpion, Umoja Pulls in $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2025
RNA Editing Medicines: Ram Aiyar on The Long Run
Ram Aiyar is today’s guest on The Long Run. Ram is the CEO of Cambridge, Mass.-based Korro Bio. The company is developing medicines that edit RNA, instead of DNA, which more people have heard about. Previously, Ram co-founded Corvidia Therapeutics and served on the management team up through its $2.1 billion acquisition by Novo Nordisk. He’s had a long and... Read More
9
Jan
2025
Novo, Variant Benefit Sharing Win, Verdiva Joins Obesity Fray & Maze Eyes IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jan
2025
Investing in Biotech: David Schenkein on The Long Run
David Schenkein is today’s guest on The Long Run. David is a general partner with GV. It’s the non-strategic corporate venture firm formerly known as Google Ventures. GV is backed by a single limited partner, Alphabet, and has $10 billion in assets under management in 400 active portfolio companies working in tech and life sciences. In this conversation, we talk... Read More
19
Dec
2024
Vertex Pain Drug Fails, Puretech Delivers for IPF, Merck Dumps TIGIT, LAG3 Antibodies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Dec
2024
The Past, Present and Future of RNAi Therapies: Kevin Fitzgerald on The Long Run
Today’s guest on The Long Run is Kevin Fitzgerald. Kevin is the chief scientific officer of Cambridge, Mass.-based Alnylam Pharmaceuticals. He joined the company way back in 2005, when it was aspiring to create a new class of RNA interference medicines. These are sometimes referred to as “gene silencing” drugs. They are designed to shut down the production of disease-related... Read More
12
Dec
2024
ASH Recap, Dimension Captures $500M, & AbbVie’s New Parkinson’s Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
Dimension Raises $500M to Seize the Tech-Driven Biology Future
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
ASH Highlights: Beam Base Editing, Novo’s Oral Pill Advance for Sickle Cell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Dec
2024
Lilly Beats Novo, Amgen’s So-So Obesity Data & Atlas Stays Lean & Mean
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.